This HTML5 document contains 118 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00250/identifier/wikipedia/
n30http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00250/identifier/pharmgkb/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/mesh/concept/
n9http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00250/identifier/kegg-compound/
n17http://linked.opendata.cz/resource/drugbank/dosage/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00250/identifier/bindingdb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00250/identifier/pubchem-compound/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00250/identifier/pubchem-substance/
n6http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB00250/identifier/kegg-drug/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00250/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n31http://www.rxlist.com/cgi/generic/
n13http://linked.opendata.cz/resource/drugbank/patent/
n32http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00250/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n25http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00250/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00250/identifier/chebi/
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00250
rdf:type
n3:Drug
n3:description
A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)
n3:dosage
n17:271B3E71-363D-11E5-9242-09173F13E4C5 n17:271B3E72-363D-11E5-9242-09173F13E4C5 n17:271B3E73-363D-11E5-9242-09173F13E4C5 n17:271B3E74-363D-11E5-9242-09173F13E4C5
n3:group
approved investigational
n3:halfLife
28 hours (range 10-50 hours)
n3:indication
For the treatment and management of leprosy and dermatitis herpetiformis.
n3:manufacturer
n9:271B657A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00250 n32:DB00250
dcterms:title
Dapsone
adms:identifier
n11:46505300 n12:PA449211 n14:2955 n15:D00592 n16:0469-5005-03 n18:C07666 n19:2849 n20:DB00250 n21:50029764 n22:4325 n28:Dapsone
n3:mechanismOfAction
Dapsone acts against bacteria and protozoa in the same way as sulphonamides, that is by inhibiting the synthesis of dihydrofolic acid through competition with para-amino-benzoate for the active site of dihydropteroate synthetase. The anti-inflammatory action of the drug is unrelated to its antibacterial action and is still not fully understood.
n3:packager
n9:271B6574-363D-11E5-9242-09173F13E4C5 n9:271B6575-363D-11E5-9242-09173F13E4C5 n9:271B6572-363D-11E5-9242-09173F13E4C5 n9:271B6573-363D-11E5-9242-09173F13E4C5 n9:271B6578-363D-11E5-9242-09173F13E4C5 n9:271B6579-363D-11E5-9242-09173F13E4C5 n9:271B6576-363D-11E5-9242-09173F13E4C5 n9:271B6577-363D-11E5-9242-09173F13E4C5 n9:271B6570-363D-11E5-9242-09173F13E4C5 n9:271B6571-363D-11E5-9242-09173F13E4C5 n9:271B656E-363D-11E5-9242-09173F13E4C5 n9:271B656F-363D-11E5-9242-09173F13E4C5
n3:patent
n13:2265461
n3:routeOfElimination
Renal
n3:synonym
DAPSONE Bis(P-aminophenyl) sulfone 4-(4-amino-Benzenesulfonyl)-phenylamine P-Aminophenyl sulfone 4-(4-Aminophenylsulfonyl)benzenamine 4,4'-Diaminodiphenylsulfone Dapsonum Bis(4-aminophenyl)sulfone P,P-Sulphonylbisbenzamine 4,4'-Sulfonylbisaniline DIAPHENYLSULFONE DADPS DDS 4,4'-Dapsone 4,4'-sulfonyldianiline P,P-Sulphonylbisbenzenamine Dapsona 4-Aminophenyl sulfone 1,1'-Sulfonylbis[4-aminobenzene] 4,4'-Sulfonylbisbenzenamine 1,1'-Sulfonylbis(4-aminobenzene) 4-(4-Aminophenylsulfonyl)aniline 4,4'-Diaminodiphenyl sulphone P,P'-diaminodiphenyl sulfone 4,4'-Diaminodiphenyl sulfone 4,4'-Sulfonyldianilin 4,4'-Sulfonylbisbenzeneamine
n3:toxicity
Overdosage might be expected to produce nasal congestion, syncope, or hallucinations. Measures to support blood pressure should be taken if necessary.
n7:hasAHFSCode
n30:08-16-92
n3:foodInteraction
Take without regard to meals.
n3:proteinBinding
70 to 90%
n3:synthesisReference
Weijiard, J.and Messerly, J.P.; U.S. Patent 2,385,899; October 2,1945; assigned to Merck & Co., Inc.
n26:hasConcept
n27:M0005661
foaf:page
n25:dapsone.html n31:dapsone.htm
n3:IUPAC-Name
n4:271B3E79-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3E7F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3E7E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3E7B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3E7C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3E7D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3E8E-363D-11E5-9242-09173F13E4C5 n4:271B3E77-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3E75-363D-11E5-9242-09173F13E4C5 n4:271B3E78-363D-11E5-9242-09173F13E4C5 n4:271B3E90-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3E76-363D-11E5-9242-09173F13E4C5 n4:271B3E91-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B3E92-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:D10AX05 n8:J04BA02
n3:H-Bond-Acceptor-Count
n4:271B3E85-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3E86-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3E80-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3E81-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3E83-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3E82-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3E84-363D-11E5-9242-09173F13E4C5
n3:absorption
Bioavailability is 70 to 80% following oral administration.
n3:affectedOrganism
Mycobacterium leprae Mycobacteria
n3:casRegistryNumber
80-08-0
n3:category
n3:containedIn
n23:271B657B-363D-11E5-9242-09173F13E4C5 n23:271B657C-363D-11E5-9242-09173F13E4C5 n23:271B657F-363D-11E5-9242-09173F13E4C5 n23:271B657D-363D-11E5-9242-09173F13E4C5 n23:271B657E-363D-11E5-9242-09173F13E4C5 n23:271B3E70-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B3E8A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3E8C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3E8D-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B3E8F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3E89-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3E88-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3E8B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3E7A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3E87-363D-11E5-9242-09173F13E4C5